Skip to Content

Analysts Forecast Ionis Pharmaceuticals, Inc. Earnings for Fiscal Year 2022 (NASDAQ:IONS)

Analysts Forecast Ionis Pharmaceuticals, Inc. Earnings for Fiscal Year 2022 (NASDAQ:IONS)

IONS, manufactured by Ionis Pharmaceuticals, Inc. The analysts at William Blair for Ionis Pharmaceuticals lowered their expectations for the company’s earnings per share for the fiscal year 2022 in a research note published on Monday, January 9. This year, the business will have earnings of $1.87 per share, which is lower than the earlier projection that Minter had made for William Blair, which was $1.85 per share. At Ionis Pharmaceuticals, the current earnings forecast for the entire year is $2.43 per share, and it is expected that this number will not change. During the fourth fiscal quarter of 2022, William Blair anticipated that Ionis Pharmaceuticals would record a loss in revenue of $0.33 per share. Earnings per share (EPS) of $0.11 for the first quarter of 2023, $0.85 for the second quarter, $0.86 for the third quarter, and $0.89 for the fourth quarter of 2023, with earnings for the full fiscal year of either $2.72% or $2.79%, respectively.

On November 9, the most recent earnings report for Ionis Pharmaceuticals, traded on the NASDAQ under the symbol IONS, was made public. Earnings per share for the company came in at $0.33 for the quarter, which was $0.41 higher than the consensus estimate of earnings per share for the period, which was $0.7. In other words, the actual earnings per share were $0.33, which was $0.41 higher than the estimate of $0.7. In addition, the company reported quarterly revenue of $160 million, which is significantly higher than the estimates provided by industry professionals, which were $149.48 million. During the period covered by the report, Ionis Pharmaceuticals was able to generate a return on equity of 1.18% and a net margin of 0.91%.

When trading started on Thursday, the price of a share of Ionis Pharmaceuticals was $37.95. The simple moving average of the company’s stock price over the past 50 days is $39.97, while the average price over the last 200 days is $41.73. The ratio of total assets to current assets is 7.59; the ratio of quick assets to current assets is 7.59; and the ratio of total assets to current assets is also 7.59. The ratio of debt to equity is 2.10. The business currently has a beta of 0.54 and is valued at $5.39 billion by the market. It has a beta of and a price-to-earnings ratio of -316.22. During the last year, the share price of Ionis Pharmaceuticals moved in a range that went from $28 to $48.82. The price as of right now is $28.

In recent times, several other brokerages, in addition to IONS, have made statements regarding their perspectives on the company. Piper Sandler increased their price objective on Ionis Pharmaceuticals’ shares from $58.00 to $60.00 in a report published on Wednesday, November 9. Barclays raised their price objective on shares of Ionis Pharmaceuticals to $44.00 within a research report made available on Tuesday, November 15. Ionis Pharmaceuticals’ shares were mentioned for the very first time on StockNews.com’s coverage on Wednesday, October 12, the first trading day after the market opened. They advised their clients to “hold” the stock moving forward. The price objective that SVB Leerink has placed on shares of Ionis Pharmaceuticals has been reduced from $30.00 to $26.00, and the firm has assigned the stock a rating of “market perform.” The research report was published on November 10.

Last but not least, in a research report made public on November 10, Citigroup upgraded their rating of Ionis Pharmaceuticals from “sell” to “hold” and increased their price objective on the stock from $28.00 to $31.00. In addition, two research analysts recommended selling the stock, three recommended holding onto the stock, and three experts recommended purchasing the stock. According to data presented on Bloomberg.com, the current rating for Ionis Pharmaceuticals is “Hold,” and the average price objective for the company is $43.00. This information was obtained from various financial analysts.

Recent transactions by institutional investors have resulted in changes to the proportion of the company’s stock held by these investors. During the first three months of 2018, Raymond James Financial Services Advisors Inc. increased the proportion of Ionis Pharmaceuticals stock owned by 3.3%. Raymond James Financial Services Advisors Inc. now has 50,585 shares of the company’s stock, valued at $1,874,000, after purchasing an additional 1,604 shares during the period in question. This brings the company’s total number of shares to 50,585. In addition, American Century Companies Inc. shelled out approximately 207 thousand dollars over the first three months of 2018 to purchase a larger stake in Ionis Pharmaceuticals. US Bancorp DE increased the percentage of Ionis Pharmaceuticals stock owned by 12.3% during the first three months of the current year. US Bancorp DE currently holds 21,458 shares, with a value of $795,000. This is because the company purchased 2,343 additional shares during the period in question. During the first three months of this year, PNC Financial Services Group Inc. increased the percentage of Ionis Pharmaceuticals stock that is owned by 9.4%. Following the acquisition of an additional 831 shares during the period in question, PNC Financial Services Group Inc. now holds 9,662 shares of the company’s stock. The current market price gives the company a market value of $358,000. MetLife Investment Management LLC completed a new investment in Ionis Pharmaceuticals during the first quarter of this year, which brings us to our last and most important point. Approximately 318 thousand dollars were invested in this venture. To the tune of 87.32 percent, the company shares are owned by institutional investors and hedge funds.

Ionis Pharmaceuticals, Inc. uses antisense technology to produce and distribute human medicinal drugs. These processes take place at Ionis Pharmaceuticals’ facilities. Ionis Core and Akcea Therapeutics are the two business divisions that the company is organized under to conduct its daily operations. Ionis Core is in charge of developing a therapeutic pipeline, and a cutting-edge drug discovery platform is one of the primary tools it utilizes in this process. For example, medicines designed to treat cardiometabolic conditions are being researched, developed, and distributed by a company named Akcea Therapeutics.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *